Zobrazeno 31 - 40
of 145
pro vyhledávání: '"Muneer H. Abidi"'
Autor:
Mei-Jie Zhang, Vivek Roy, Shaji Kumar, Angela Dispenzieri, Dan T. Vogl, Jiaxing Huang, Baldeep Wirk, Parameswaran Hari, Daniel J. Landsburg, Robert Peter Gale, Muneer H. Abidi, Xiaobo Zhong, Tamila L. Kindwall-Keller, Jennifer M. Bird, Ravi Vij, Reinhold Munker, Manish Sharma, Hillard M. Lazarus, Robert A. Kyle, Cesar O. Freytes
Publikováno v:
Biology of Blood and Marrow Transplantation. 21(2):335-341
Patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT) typically receive a finite period of initial therapy before ASCT. It is not clear if patients with suboptimal (less than a partial) response to initi
Autor:
Richard Manasa, Lawrence G. Lum, Zaid Al-Kadhimi, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Gregory Dyson, Muneer H. Abidi, Divaya Bhutani, Joseph P. Uberti
Publikováno v:
Biology of Blood and Marrow Transplantation. 21:159-164
Gastrointestinal (GI) graft-versus-host disease (GVHD) is one of the most common causes of morbidity and mortality after allogeneic stem cell transplantation. In addition, cytomegalovirus (CMV) infection of the gastrointestinal tract can complicate t
Autor:
Abhinav Deol, Zaid Al-Kadhimi, Lawrence G. Lum, Lois Ayash, Muneer H. Abidi, Wei Chen, Voravit Ratanatharathorn, Edmund K. Waller, Zartash Gul, Daryn Smith, Joseph P. Uberti
Publikováno v:
Biology of Blood and Marrow Transplantation. 20(7):979-985
Both acute and chronic graft-versus-host disease (GVHD) are major causes of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). The optimal pharmacological regimen for GVHD prophylaxis is unclear
Autor:
Lawrence G. Lum, Abhinav Deol, Voravit Ratanatharathorn, Lois Ayash, Simon Cronin, Zaid Al-Kadhimi, Kendra Mellert, Joseph P. Uberti, Muneer H. Abidi, Muthu Veeraputhiran, Tania Jain
Publikováno v:
Journal of Clinical Apheresis. 29:293-298
We report our experience of collecting stem cells in patients who failed to mobilize sufficient hematopoietic stem cell (HSC) using plerixafor (P) in the initial mobilization attempt. Twenty four patients were identified who failed a first mobilizati
Autor:
Miguel Angel Diaz, Taiga Nishihori, Amrita Krishnan, Muneer H. Abidi, Sachiko Seo, Siddhartha Ganguly, Rammurti T. Kamble, Anita D'Souza, Angelo Maiolino, David I. Marks, Kenneth R. Meehan, Adetola A. Kassim, Joe Mikhael, Hillard M. Lazarus, David H. Vesole, Jack Aiello, Cindy Lee, Asad Bashey, Cesar O. Freytes, Gorgun Akpek, Racquel Innis-Shelton, Ravi Vij, Raymond L. Comenzo, Jiaxing Huang, Robert F. Cornell, Tamila L. Kindwall-Keller, Ayman Saad, Tomer M Mark, Richard F. Olsson, Jan Cerny, Dan T. Vogl, Muthalagu Ramanathan, Robert Peter Gale, Leona Holmberg, Mehdi Hamadani, Parameswaran Hari, Shahrukh K. Hashmi, Nasheed Hossain, Mei-Jie Zhang, Jean A. Yared, Shaji Kumar, Saad Z. Usmani, Rajneesh Nath, Luciano J. Costa, Mohamed A. Kharfan-Dabaja, Robert A. Kyle, Baldeep Wirk, Yago Nieto, Qaiser Bashir
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Bortezomib (V), lenalidomide (R), cyclophosphamide (C), and dexamethasone (D) are components of the most commonly used modern doublet (RD, VD) or triplet (VRD, CVD) initial induction regimens before autologous hematopoietic cell transplantation (AHCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0412646c8c6f1e02f8fb6a4e7cae169f
https://europepmc.org/articles/PMC5346183/
https://europepmc.org/articles/PMC5346183/
Autor:
Mohan C. Thakuri, Joshua Epstein, Muneer H. Abidi, Stephen P. Kahanic, Angela Dispenzieri, S. Vincent Rajkumar, Robert Z. Orlowski, Rachael Sexton, Frederic J. Reu, Christopher M. Reynolds, Bart Barlogie, Antje Hoering, Brian G.M. Durie
Publikováno v:
Blood. 132:1992-1992
Background: SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). The primary end point was progression-free survival (PFS) using a pre-specified one-sided strati
Autor:
Zaid Al-Kadhimi, Hiroshi Yano, Muneer H. Abidi, Dana Schalk, Lois Ayash, Melissa Dufresne, Archana Thakur, Abhinav Deol, Patricia A. Steele, Qin Liu, Lawrence G. Lum, Joseph P. Uberti, Voravit Ratanatharathorn, Elyse N. Tomaszewski, Alice Mitchell, Cassara Pray
Publikováno v:
Biology of Blood and Marrow Transplantation. 19(6):925-933
A phase I trial of infusing anti-CD3 × anti-CD20 bispecific antibody (CD20Bi) armed activated T cells (aATC) was conducted in high-risk/refractory non-Hodgkin's lymphoma patients to determine whether aATC infusions are safe, affect immune recovery,
Autor:
Lawrence G. Lum, Voravit Ratanatharathorn, Lois Ayash, Divaya Bhutani, Jeffrey A. Zonder, Zaid Al-Kadhimi, Abhinav Deol, Muneer H. Abidi, Nishant Tageja, Joseph P. Uberti, Jason Valent, Judith Abrams
Publikováno v:
Supportive Care in Cancer. 21:2437-2442
Lenalidomide (LEN) is a relatively new and very effective therapy for multiple myeloma (MM). Prior LEN therapy is associated with an increased risk of peripheral blood stem cell collection (PBSC) failure, particularly with filgrastim (G-CSF) alone. W
Autor:
Zaid Al-Kadhimi, Abhinav Deol, Lawrence G. Lum, Muneer H. Abidi, Lois Ayash, Joseph P. Uberti, Ashiq Masood, Voravit Ratanatharathorn, Judith Abrams
Publikováno v:
Bone Marrow Transplantation. 48:1112-1116
We report the long-term follow up of 49 patients (pts) enrolled on plerixafor compassionate use protocol. Thirty-seven pts (76%) had failed one previous mobilization attempt, while 12 (24%) had failed two or more previous attempts. Using the combinat
Autor:
Nishant Tageja, Marie Ventimiglia, Rishi Agarwal, Abhinav Deol, Zaid Al-Kadhimi, Lawrence G. Lum, Judith Abrams, Muneer H. Abidi, Voravit Ratanatharathorn, Joseph P. Uberti, Jeffrey A. Zonder, Lois Ayash, Simon Cronin
Publikováno v:
Biology of Blood and Marrow Transplantation. 19(1):56-61
Melphalan 200 mg/m(2) is the standard conditioning regimen for patients with multiple myeloma (MM) with normal renal function (NRF) undergoing autologous stem cell transplant (ASCT). In an effort to escalate the dose of melphalan and to improve the e